Advanced genomic analysis will transform how we practice medicine and how doctors will treat patients, from prevention to cure, says Prof Owen P Smith.

Icon shares recovered from an early decline yesterday as the Irish clinical research and drug development services firm met fourth- quarter earnings targets, but narrowly came up short on revenue estimates.

Icon shares slipped by over 7% at one point yesterday even on the back of the Dublin-headquartered pharmaceutical and healthcare services firm reporting a 14% rise in first quarter operating profit and a 3.2% revenue increase.